BDSX Biodesix

Biodesix to Participate in Three Investor Conferences in November

Biodesix to Participate in Three Investor Conferences in November

LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences:

Craig-Hallum 15th Annual Alpha Select Conference

1x1 Meetings

Date: Tuesday, November 19, 2024

Location: New York, NY

Wolfe Research Healthcare Conference 2024

1x1 Meetings

Date: Wednesday, November 20, 2024

Location: New York, NY

Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum

Presentation and 1x1 Meetings

Presentation Date and Time: Thursday, November 21, 2024 at 1:00 PM ET

Location: New York, NY

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at .

About Biodesix

Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit .

Note: Biodesix, Nodify Lung, IQLung, GeneStrat, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT are trademarks or registered trademarks of Biodesix, Inc. ddPCR is a trademark of Bio-Rad Laboratories, Inc.

Contacts:

Media:

Natalie St. Denis



1-720-925-9285

Investors:

Chris Brinzey



1-339-970-2843



EN
29/10/2024

Underlying

BDSXBiodesix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biodesix

 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Hig...

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "B...

February 26, 2026 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Participate in Upcoming Investor Conferences

Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team will participate in two upcoming investor conferences: TD Cowen's 46th Annual Health Care ConferenceFireside Chat Date: Tuesday, March 3, 2026Fireside Chat Time: 2:30 PM ETLocation: Boston, MA Barclays 28th Annual Global Healthcare ConferenceFireside Chat Date: Wednesday, March 11, 2026Fireside Chat Time: 12:00 PM ETLocation: Miami, FL The fireside chats will be...

February 24, 2026 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results...

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the close of trading on Thursday, February 26. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this . Anal...

February 12, 2026 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Resul...

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX) (the company), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). The financial results included in this release pertaining t...

January 12, 2026 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

Biodesix to Present New Data at Two Major Upcoming Scientific Meetings Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagn...

December 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch